Association Between BCL-2-938 (C＞A) Polymorphism And Clinical Phenotype And Prognosis Of Non-hodgkin's Lymphoma(NHL)

Objectives:The study investigated the association between a novel regulatory single nucleotide polymorphism(SNP)(-938C＞A)in the inhibittory P2 B-cell CLL/lymphoma 2(BCL-2)promoter and non—hodgkin's lymphoma In a population of Guangxi Province,which is included Clinical phenotype, recent therapeutic effect,prognosis and blood toxicity.Methods:This study recruited a total of 90 NHL in GuangXi Province.The BCL-2 gene SNPs were genotyped by polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP)analysis.Association between polymorphisms and NHL were estimated by use of unconditional logistic regression using SPSS 13.0 sofeware.Uncond- itional Logistic regression was used to compute odds ratios(OR)and associated 95%confidence intervals(95 %CI)relating each of the SNPs to NHL Clinical phenotype,recent therapeutic effect,survival and blood toxicity.The odds ratios(ORs)were adjusted for age,clinical stage,performance status,estranodal involvement,serum LDH and chemotherapy cycles.Results:1.(1)In tumor malignant degree,BCL-2-938(C＞A)genotype distribution was significantly different in patients with AC/CC genotype compared to AA genotypes(all P values are below 0.05),and AC/CC genotype obviously increase the moderate and high rate malignant NHL risk(OR=7.333 and 7.615,95%CI:1.738～30.945,1.438～40.333).(2)Compared to CC genotype,AA genotype distribution is higher in tumor size=5cm than tumor size＜5cm(P=0.016,OR=7.412.95%CI:1.455～37.746).(3)No significant difference(all P values are above 0.05)was observed in the frequencies of the BCL-2 genotypes between NHL cell Category(B cell group and T/NK cell group)and estranodal involvement Amount(≤1 group and＞1 group).2.the distribution of overall genotype of the BCL-2 genes in NHL treatment index such as recent therapeutic effect(CR/PR group and SD/PD group)and survival(＜one year group and≥1 one year group,＜two year group and≥two year group)was not significantly different(all adjusted P＞0.05).3.(1)The study of correlation with blood toxicity(Ⅰ-Ⅱgroup andⅢ-Ⅳgroup), the analysis,the distribution of BCL-2-938 genotype frequencies was not significant differences(all P＞0.05).(2)The study of association between BCL-2 -938(C＞A)polymorphism and blood toxicity degree,we found AC/AA genotype compared to CC genotype increased severe Leukopenia risk(OR=3.937,5.727.95%CI:1.074～14.438,1.499～21.887),but there were not differences of the overall genotype distribution in severe anemia and Thrombocytopenia(all P>0.05).Conclusions:1.BCL-2-938 AC/CC genotype may increase the moderate and high rate malignant NHL risk,and bcl-2-938 AA genotype is association with large tumor mass(＞5cm),But BCL-2-938(C＞A)polymorphism is no association with NHL cell Category and estranodal involvement Amount.2.There might be no association between BCL-2-938(C＞A) polymorphism and recent therapeutic effect,as well as recent survival.3.Compared to CC genotype,AC/AA genotype increased severe Leukopenia risk,but there were not significantly different in severe anemia and Thrombocytopenia.